RNAi Therapeutics News and Research

RSS
RNA interference (RNAi) was discovered less than a decade ago and already there are human clinical trials in progress or planned. A major advantage of RNAi versus other anti-sense based approaches for therapeutic applications is that it utilizes cellular machinery that efficiently allows targeting of complementary transcripts, often resulting in highly potent down-regulation of gene expression.
Bio-Path awarded $244,479 federal grant for Liposomal Grb-2 Phase I clinical trial

Bio-Path awarded $244,479 federal grant for Liposomal Grb-2 Phase I clinical trial

Alnylam third quarter revenue increases from $24.2 million to $27.7 million

Alnylam third quarter revenue increases from $24.2 million to $27.7 million

IRS awards RXi Pharmaceuticals four Therapeutic Discovery Project grants

IRS awards RXi Pharmaceuticals four Therapeutic Discovery Project grants

Alnylam to present data on RNAi therapeutics for fibrotic diseases at The Liver Meeting

Alnylam to present data on RNAi therapeutics for fibrotic diseases at The Liver Meeting

Dicerna secures $4 million in second closing of Series B equity financing

Dicerna secures $4 million in second closing of Series B equity financing

EPO grants new patent to Silence Therapeutics’ RNAi structural modification technology

EPO grants new patent to Silence Therapeutics’ RNAi structural modification technology

Access Pharmaceuticals reports significant progress in Cobalamin-targeted drug-delivery program for siRNA therapies

Access Pharmaceuticals reports significant progress in Cobalamin-targeted drug-delivery program for siRNA therapies

Alnylam Pharmaceuticals publishes ALN-RSV01 Phase IIa study results

Alnylam Pharmaceuticals publishes ALN-RSV01 Phase IIa study results

RXi, EyeGate collaborate to develop RNAi therapeutics for retinal disorders

RXi, EyeGate collaborate to develop RNAi therapeutics for retinal disorders

Silence Therapeutics receives two patents for RNA interference therapeutics

Silence Therapeutics receives two patents for RNA interference therapeutics

Alnylam Pharmaceuticals to present results on RNAi therapeutics at ACS National Meeting

Alnylam Pharmaceuticals to present results on RNAi therapeutics at ACS National Meeting

Alpha-synuclein gene silencing effective for treating neurodegenerative disorders: Research

Alpha-synuclein gene silencing effective for treating neurodegenerative disorders: Research

Preclinical studies of BIND-014 to be presented at ACS National Meeting

Preclinical studies of BIND-014 to be presented at ACS National Meeting

Quark Pharmaceuticals announces option agreement with Novartis for QPI-1002 siRNA drug

Quark Pharmaceuticals announces option agreement with Novartis for QPI-1002 siRNA drug

MMV joins Pool for Open Innovation against neglected tropical diseases

MMV joins Pool for Open Innovation against neglected tropical diseases

Rxi Pharmaceuticals second-quarter net loss decreases to $2.1 million

Rxi Pharmaceuticals second-quarter net loss decreases to $2.1 million

Silence Therapeutics receives patent for RNA silencing method

Silence Therapeutics receives patent for RNA silencing method

Alnylam Pharmaceuticals reports significant progress in discovery of novel technologies for systemic delivery of RNAi therapeutics

Alnylam Pharmaceuticals reports significant progress in discovery of novel technologies for systemic delivery of RNAi therapeutics

Alnylam publishes research findings of Sort1 gene role in cardiovascular disease development

Alnylam publishes research findings of Sort1 gene role in cardiovascular disease development

Alnylam second-quarter revenues increase to $26.6 million

Alnylam second-quarter revenues increase to $26.6 million